Erasmus University Rotterdam

Xencor Appoints Bart Cornelissen as Chief Financial Officer

Retrieved on: 
Tuesday, April 9, 2024
Biotechnology, Pharmaceutical, Oncology, General Health, Health, Hospitals, Genetics, Clinical Trials, Master of Science, Bill, Erasmus University Rotterdam, Pfizer, Rotterdam School, Novartis, Business administration, Acquisition, Cancer, Protein engineering, Biology, Investment, DSM (company), Malaria, Pharmaceutical industry

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today announced the appointment of Bart Cornelissen to senior vice president and chief financial officer.

Key Points: 
  • Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today announced the appointment of Bart Cornelissen to senior vice president and chief financial officer.
  • Mr. Cornelissen has more than 20 years of experience in corporate financial planning, analysis and transaction support.
  • “Bart’s exceptional track record in financial planning and analysis, business development and organizational excellence will be of great value to Xencor as we advance our maturing clinical-stage pipeline of drug candidates and continue to explore our XmAb® platforms against novel biology,” said Bassil Dahiyat, Ph.D., president and chief executive officer at Xencor.
  • He began his career within the life sciences and global health sectors at Novartis, in roles of increasing responsibility within global financial planning and analysis.

Bicara Therapeutics Expands Clinical Team with Appointments of Jeltje Schulten, M.D., MBA, as SVP of Clinical and Medical Affairs and Rita Dalal, MBBS, MPH, as VP of Clinical Development

Retrieved on: 
Tuesday, March 26, 2024
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Carcinoma, Alkermes, Erasmus University Rotterdam, Cetuximab, Patient, SVP, ImClone Systems, Biostatistics, Merck, Epidemiology, Management, University, MBA, Merck Group, Limited partnership, MPH, Therapy, International school, PPD, Eli Lilly and Company, Marketing, Avelumab, Daiichi Sankyo

“We are very pleased to welcome Jeltje and Rita to our talented team.

Key Points: 
  • “We are very pleased to welcome Jeltje and Rita to our talented team.
  • Dr. Schulten received her medical degree from Erasmus University, Rotterdam, Netherlands and her MBA from the International School of Management RSM, Rotterdam, Netherlands.
  • Dr. Rita Dalal is a trained physician with extensive and diverse clinical research experience including in solid tumor oncology.
  • Previously, Dr. Dalal held clinical research scientist positions with Merck Sharp & Dohme Corp. and Eli Lilly and Company.

Sandoz announces nominations to the Board of Directors and leadership change

Retrieved on: 
Tuesday, March 5, 2024
Remco, J&J, Person, Chemistry, Mechanical, Growth, IMD, Swisscom, University, Lufthansa, Organization, 10x Genomics, Annual general meeting, Erasmus University Rotterdam, Johnson & Johnson, MBA, Gesellschaft mit beschränkter Haftung, Genomics, Retirement, Flexner Report, Harvard Medical School, HST, CFO, Massachusetts Institute of Technology, Merck, Harvard University, Executive Committee, Doctor of Philosophy, Annual, KPMG, Management

Gilbert Ghostine, Sandoz Chairman, said: "Our company evolves, and so does our leadership team.

Key Points: 
  • Gilbert Ghostine, Sandoz Chairman, said: "Our company evolves, and so does our leadership team.
  • I am pleased we can propose exceptional people in science and in business for election to the Board of Directors this year.
  • The new Board talent maintains the complementarity of expertise and experience in the areas relevant to Sandoz.
  • The following persons are recommended for election to the Board of Directors at the Annual General Meeting on April 30, 2024:

Northern Trust Asset Management Names Director of Quantitative Solutions, International

Retrieved on: 
Tuesday, January 23, 2024
Personal Finance, Finance, Banking, Professional Services, Asset Management, Financial analyst, Head, Research, Alternative investment, Multimedia, International, Erasmus University Rotterdam, CIO, Bart, Journal, Doctor of Philosophy, Robeco

Northern Trust Asset Management (NTAM), a leading global investment management firm with $1.18 trillion in assets under management as of December 31, 2023, announced today that Milan Vidojevic has joined NTAM as Director, Quantitative Solutions, International.

Key Points: 
  • Northern Trust Asset Management (NTAM), a leading global investment management firm with $1.18 trillion in assets under management as of December 31, 2023, announced today that Milan Vidojevic has joined NTAM as Director, Quantitative Solutions, International.
  • View the full release here: https://www.businesswire.com/news/home/20240123372586/en/
    Milan Vidojevic has joined Northern Trust Asset Management as Director, Quantitative Solutions, International.
  • Additionally, Bart van Vliet joins NTAM in Amsterdam as Quantitative Solutions Associate, International.
  • These appointments follow the recent hiring of Guido Baltussen Ph.D. as Head of Quantitative Strategies, International.

Santhera Appoints Executive Committee Members as it Transitions into Commercial Stage

Retrieved on: 
Thursday, December 7, 2023
Neuro-ophthalmology, European Commission, Cardiology, Rheumatology, Executive Committee, Medical director, CMC, CCO, CDMO, CGMP, Doctor of Philosophy, Actelion, Civil service commission, Vamorolone, Endocrinology, DSM-IV codes, Erasmus University Rotterdam, Patient, Head, Organization, Neurology, Technical

Both will join the six-member Executive Committee effective January 1, 2024.

Key Points: 
  • Both will join the six-member Executive Committee effective January 1, 2024.
  • “Santhera is transitioning to the commercial phase and will make AGAMREE® (vamorolone) available to patients in Europe starting in Germany in early 2024, subject to approval by the European Commission.
  • Notably, he was instrumental in establishing Santhera’s European commercial operations and successfully launching the rare disease product RAXONE® in Europe which was later divested to Chiesi Group.
  • Before joining Santhera, Geert Jan held positions as Medical Director, Business Unit Director and General Manager in start-up teams in Serono, Actelion and InterMune.

Esker Designates Catherine Plasse as New CFO

Retrieved on: 
Tuesday, November 21, 2023
Mobile, Wireless, Technology, Payments, Finance, Security, Professional Services, Software, Data Management, Asset Management, Artificial Intelligence, Financial analyst, Customer service, CFO, Erasmus University Rotterdam, Transition, Northumbria University, Automation, Controller, Financial management, EDHEC Business School, HEC Paris, Certification, ESG, Management, Esker

Reporting to Emmanuel Olivier, Esker COO on the Board of Directors, Plasse will manage and coordinate Esker’s Finance teams worldwide and join Esker’s Associate Board of Directors.

Key Points: 
  • Reporting to Emmanuel Olivier, Esker COO on the Board of Directors, Plasse will manage and coordinate Esker’s Finance teams worldwide and join Esker’s Associate Board of Directors.
  • Plasse will also play a crucial role in steering the operational performance of Esker by managing budgetary and control aspects.
  • Plasse held various Financial Analyst and Controller positions at Suez Group, most notably as CFO in the U.S. for three years.
  • “I’m delighted to be joining Esker, an innovative company that plays a key role in the digital transformation of businesses worldwide,” said Plasse.

Northern Trust Asset Management Names New International Head of Quantitative Strategies

Retrieved on: 
Wednesday, November 15, 2023
Banking, Asset Management, Professional Services, Finance, Journal of Financial Economics, Economics, Tinbergen Institute, American Economic Review, Head, Bangladesh Technical Education Board, International, Financial economics, Erasmus University Rotterdam, Investment, Journal, Doctor of Philosophy, Robeco, NN Group, NN Investment Partners, Growth

Northern Trust Asset Management (NTAM), a leading global investment management firm with $1.09 trillion in assets under management as of September 30, 2023, announced today that Guido Baltussen, Ph.D. has joined NTAM as Head of Quantitative Strategies, International.

Key Points: 
  • Northern Trust Asset Management (NTAM), a leading global investment management firm with $1.09 trillion in assets under management as of September 30, 2023, announced today that Guido Baltussen, Ph.D. has joined NTAM as Head of Quantitative Strategies, International.
  • In this newly created role, Baltussen will lead NTAM’s international quantitative strategies investments to support our growth, including quantitative research and innovation, thought leadership, and investment strategy.
  • Baltussen will report to Michael Hunstad, Northern Trust Asset Management’s Deputy Chief Investment Officer and Chief Investment Officer of Global Equities.
  • Previously, he was head of quantitative research for multi-asset strategies at NN Investment Partners and a quantitative investment strategist with ING Investment Management.

Zimmer Biomet Announces Key Updates to Company's Executive Leadership Team

Retrieved on: 
Tuesday, September 5, 2023
Pennsylvania State University, Bachelor's degree, Medicine, Bachelor, UnitedHealth Group, Hip, University, Senior, Marketing, Erasmus University Rotterdam, Business economics, Business, MBA, Innovation, Thomas Jefferson University, Economics, Strategic leadership, Medtronic, University of Richmond, Acquisition, Novartis, Patient, Thomas Jefferson University Hospital, Region, Chief innovation officer, Michelin, Teleflex, Orthopedic surgery, NYSE, Zuilen, Covidien, Management, Virginia Tech, Adult, Optum

WARSAW, Ind., Sept. 5, 2023 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced key updates to the Company's Executive Leadership Team. Wilfred van Zuilen has been promoted to Group President, EMEA; Mark Bezjak was promoted to President of the Americas; and Chief Science, Technology and Innovation Officer Nitin Goyal, M.D. has been appointed to the Executive Leadership Team, all reporting directly to President and Chief Executive Officer Ivan Tornos.

Key Points: 
  • Appointed to Executive Leadership Team
    WARSAW, Ind., Sept. 5, 2023 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced key updates to the Company's Executive Leadership Team.
  • has been appointed to the Executive Leadership Team, all reporting directly to President and Chief Executive Officer Ivan Tornos.
  • "The expansion of Zimmer Biomet's Executive Leadership Team coincides with our renewed focus on commercial execution and innovation to drive the Company forward," said Mr. Tornos.
  • Wilfred Van Zuilen Promotion to Group President, EMEA
    Mr. van Zuilen joined Zimmer Biomet in June 2021 as President, EMEA.

Churchill Franklin Automotive Launches Airbag Alert News Service

Retrieved on: 
Wednesday, August 30, 2023
Component, Reuters, Senior, Marketing, Harvard University, The Wall Street Journal, NPR, Harris, Takata Corporation, Pennsylvania State University, Corporate communication, TRW Automotive, Erasmus University Rotterdam, Airbag, University of Michigan, Upham, Automotive industry, Transport, Ford Motor Company, Bloomberg News, CNBC, Eastern Michigan University, Forecasting, J.D. Power, Financial Times, Associate, Ideation, Associated, Radio, Harris Interactive, Ironworks, Management, The New York Times, Nielsen

Nanjing Hongguang Autoliv Vehicle Safety Systems Co. Ltd

Key Points: 
  • Nanjing Hongguang Autoliv Vehicle Safety Systems Co. Ltd
    East Joy Long Motor Airbag Co., Ltd.
    Churchill Franklin’s Founder & CEO Scott Upham is the senior editor of the Airbag Alert publication.
  • An internationally acclaimed corporate strategist, Scott Upham is a trusted advisor to the world’s most influential businesses and institutions.
  • Prior to founding Churchill Franklin, Upham was Founder & CEO of Valient Market Research, Senior Vice President, Automotive & Transportation Research at Harris Interactive (now Nielsen), Senior Director, Global Automotive Systems & Component Forecasting at J.D.
  • Upham began his career at Ford Motor Company and subsequently held senior corporate marketing and communications posts at TRW Automotive, Kelsey-Hayes and Takata Corporation.

Citryll Announces Appointments of Eduardo Bravo as CEO and Tim Schenk as CBO

Retrieved on: 
Tuesday, August 29, 2023
Biotechnology, Pharmaceutical, Health, SPAC, IPO, Analytical chemistry, Therapy, University, Doctor of Philosophy, Takeda, CSO, Phase II, Erasmus University Rotterdam, Business, MBA, Business administration, EQT, Fellow of the Academy of Medical Sciences, Acquisition, INSEAD, Hidradenitis suppurativa, Janssen Vaccines, Immune-mediated inflammatory diseases, Sanofi, In Ictu Oculi, Johnson & Johnson, TiGenix, Commercial, GSK plc, Rheumatoid arthritis, Janssen Pharmaceuticals, Management, Citryl-CoA lyase

Citryll , a clinical-stage biotech company developing first-in-class therapeutics to treat immune-mediated inflammatory diseases, today announced the appointment of Eduardo Bravo as Chief Executive Officer.

Key Points: 
  • Citryll , a clinical-stage biotech company developing first-in-class therapeutics to treat immune-mediated inflammatory diseases, today announced the appointment of Eduardo Bravo as Chief Executive Officer.
  • In addition, Citryll has appointed Tim Schenk, Ph.D., as Chief Business Officer.
  • Dr. Schenk brings with him a broad background in business and commercial development across the life sciences industry.
  • As Mr. Bravo steps into the CEO role, Eric Meldrum, Ph.D., will fully resume his position as Chief Scientific Officer at Citryll.